ALUMIS INC (ALMS) Stock Price & Overview
NASDAQ:ALMS • US0223071020
Current stock price
The current stock price of ALMS is 22.52 USD. Today ALMS is down by -2.3%. In the past month the price decreased by -9.23%. In the past year, price increased by 350.4%.
ALMS Key Statistics
- Market Cap
- 2.865B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.50
- Dividend Yield
- N/A
ALMS Stock Performance
ALMS Stock Chart
ALMS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALMS. When comparing the yearly performance of all stocks, ALMS is one of the better performing stocks in the market, outperforming 98.18% of all stocks.
ALMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALMS. While ALMS has a great health rating, there are worries on its profitability.
ALMS Earnings
On March 19, 2026 ALMS reported an EPS of -0.94 and a revenue of 1.93M. The company beat EPS expectations (5.77% surprise) and missed revenue expectations (-20.39% surprise).
ALMS Forecast & Estimates
17 analysts have analysed ALMS and the average price target is 39.17 USD. This implies a price increase of 73.93% is expected in the next year compared to the current price of 22.52.
For the next year, analysts expect an EPS growth of 45.7% and a revenue growth -72.5% for ALMS
ALMS Groups
Sector & Classification
ALMS Financial Highlights
Over the last trailing twelve months ALMS reported a non-GAAP Earnings per Share(EPS) of -5.5. The EPS increased by 45.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.07% | ||
| ROE | -80.76% | ||
| Debt/Equity | 0 |
ALMS Ownership
ALMS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.59 | 878.257B | ||
| JNJ | JOHNSON & JOHNSON | 20.42 | 573.153B | ||
| MRK | MERCK & CO. INC. | 23.6 | 297.058B | ||
| PFE | PFIZER INC | 9.15 | 155.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 118.543B | ||
| ZTS | ZOETIS INC | 16.98 | 50.689B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.37 | 27.937B | ||
| VTRS | VIATRIS INC | 5.55 | 16.104B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.68 | 11.863B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.122B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.497B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.072B | ||
| CORT | CORCEPT THERAPEUTICS INC | 79.8 | 4.606B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALMS
Company Profile
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 233 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Company Info
IPO: 2024-06-28
ALUMIS INC
280 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 233
Phone: 16502316625
ALUMIS INC / ALMS FAQ
Can you describe the business of ALUMIS INC?
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 233 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
What is the current price of ALMS stock?
The current stock price of ALMS is 22.52 USD. The price decreased by -2.3% in the last trading session.
What is the dividend status of ALUMIS INC?
ALMS does not pay a dividend.
What is the ChartMill rating of ALUMIS INC stock?
ALMS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ALUMIS INC (ALMS)?
ALUMIS INC (ALMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.5).
Can you provide the upcoming earnings date for ALUMIS INC?
ALUMIS INC (ALMS) will report earnings on 2026-05-12.
What is the Short Interest ratio of ALUMIS INC (ALMS) stock?
The outstanding short interest for ALUMIS INC (ALMS) is 13.09% of its float.